Navigation Links
IDM Pharma Reports Third Quarter 2007 Financial Results
Date:11/8/2007

low a more robust analysis of L-MTP- PE, will not continue to support its overall survival benefit in osteosarcoma, and may not provide substantial evidence for the potential regulatory approval of L-MTP-PE, the timing of the FDA's and EMEA's review of the submissions for marketing approval of L-MTP-PE, the ability of the Company to respond to questions raised by the FDA and EMEA in a satisfactory manner, the time needed to respond to any issues raised by the FDA and EMEA with regard to regulatory submissions for L-MTP-PE, the possibility that regulatory authorities may not consider preclinical and early clinical development work conducted by Ciba-Geigy and efficacy data from the Phase 3 trial conducted by Children's Oncology Group as adequate for their assessment of L-MTP-PE, which may cause delays in review, may result in the regulatory authorities requiring the Company to conduct additional clinical trials, or may result in a determination by the regulatory authorities that the data does not support marketing approval, whether regulatory authorities will approve L-MTP-PE within the time frame expected by the Company or at all, and whether the Company will be able to manufacture and commercialize L-MTP-PE even if it is approved by regulatory authorities. Other risks affecting the Company and its drug development programs include whether the Company or any of its collaborators will be able to develop pharmaceutical products using the technologies of the Company, whether clinical trial results to date are predictive of results of any future clinical trials, risks associated with completing clinical trials of product candidates, risks involved in the regulatory approval process for the Company's product candidates, the possibility that clinical testing may reveal undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operat
'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... JZ Fitness, an independently operated wellness ... programming, authorship, international lecturing and community wellness, created by ... release of the JZ Fitness nutrition app, available on ... thousands of individuals on nutrition, Jenn Zerling (“JZ”) has ... require calorie counting or cumbersome food logging. ...
(Date:10/20/2014)... Diego, CA (PRWEB) October 20, 2014 AttorneyOne.com, ... all the latest information from the FDA on Sit ... on October 10 not to purchase or use Sit and ... Sit and Slim II is promoted as weight loss product ... Sibutramine, removed from the market in 2010 for safety reasons, ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Succeed is proud ... local companies who participated in the Every Body Walk! ... a public awareness project that encourages workers to be more ... Step 10,000 Program, which concluded at the end of September, ... of cities and metro areas. Participating companies gave their ...
(Date:10/20/2014)... Final Cut Pro X Plugin developers from Pixel Film ... FCPX filmmakers . , “Fun, cool, and simple are ... Says Christina Austin, CEO of Pixel Film Studios. “It has ... comes with all the tools needed for a full ... added style, a title screen for an introduction, two lower ...
(Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... to be introduced in the U.S., has a lot to ... time when our country recognizes the achievements and contributions of ... marks the anniversary for Punzoné, and today it shares its ... and take a trip to Italy - even if it ...
Breaking Medicine News(10 mins):Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4
... Latest Projections WASHINGTON , May 12 The ... today highlight the imperative to act immediately to address ... the American Academy of Actuaries . The financial ... during the past year and inaction will only make ...
... 12 Pharmos Corporation (Pink Sheets: PARS) today reported results ... recorded a net loss of $3.7 million, or $0.14 per ... loss of $3.6 million, or $0.14 per share, in the ... at March 31, 2009.The slight increase in net loss for ...
... supposed problems of Social Security based on the Social ... U.S. House Aging Committee Director Bob Weiner. Weiner, who ... under Rep. Claude Pepper and later worked for Reps. ... said, "Everyone forgets that Social Security has already absorbed ...
... AmericansWASHINGTON, May 12 Today the Kronos Longevity ... on top longevity research findings over the last ... , http://www.kronosinstitute.org/publications/reports/sos_2009.cfm Director ... Gleason, Ph.D., Associate Scientist/Geriatric Neuropsychologist from the ...
... Barielle is your Summer Savior for Resolving Hard Cuticles. Barielle,s hand cream ... summer. , ... New York, NY (PRWEB) May 14, 2009 -- Pretty ... to toe with a perfect manicure easy enough to execute at home. ...
... research, better adherence to recommendations needed, study suggests , , ... widely varying policies on organ donation after cardiac death ... the United States, Puerto Rico and Canada about their ... received responses from 105 hospitals, and found that 72 ...
Cached Medicine News:Health News:Actuaries: Trustees' Reports Warn of Looming Financial Challenges Facing Retirement Programs 2Health News:Actuaries: Trustees' Reports Warn of Looming Financial Challenges Facing Retirement Programs 3Health News:Pharmos Corporation Reports 2009 First Quarter Results 2Health News:Pharmos Corporation Reports 2009 First Quarter Results 3Health News:Pharmos Corporation Reports 2009 First Quarter Results 4Health News:Pharmos Corporation Reports 2009 First Quarter Results 5Health News:Social Security 'Problems' Are 'Misplaced Scare Tactics' and Media Missing Story of Solvency, Says Former Congressional Aging Committee Chief of Staff Bob Weiner 2Health News:KLRI Releases 3rd Annual Report On Year's Top Longevity Research Findings 2Health News:KLRI Releases 3rd Annual Report On Year's Top Longevity Research Findings 3Health News:KLRI Releases 3rd Annual Report On Year's Top Longevity Research Findings 4Health News:Resolve Hard Cuticles this Summer with Barielle Hand Cream 2Health News:Organ Donation Policies Vary Among Children's Hospitals 2
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... development of therapeutic antibodies, today announced the appointment ... Development Officer. Dr. Londei will lead the preclinical ... "We are pleased to welcome ... Hamza Suria , President and Chief Executive ...
(Date:10/20/2014)... , Oct. 20, 2014   Mary,s Medicinals ... Caring, is a 4-Star Sponsor of Operation Grow4Vets ... with unique products, programs and services to assist them ... Key Facts: , An ever-increasing ... a safe and effective treatment for pain, Post-traumatic Stress ...
(Date:10/19/2014)... Wash. , Oct. 20, 2014 CTI ... that it will report its third quarter 2014 financial ... of the U.S. financial markets. Following the announcement, members ... call to discuss the results and provide a general ... Access to the event can be obtained as follows: ...
Breaking Medicine Technology:AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... N.J., Dec. 23, 2010 Dey Pharma, L.P. today ... Meda, a leading international specialty pharma company headquartered in ... EpiPen® (epinephrine) Auto-Injector in Europe. EpiPen Auto-Injector is used ... can occur quickly, often within a couple of minutes, ...
... Partners announced today that it has updated coverage on ... ) ("the Company") and maintains its twelve month target price ... "DAVANAT®, the Company,s lead product candidate, could potentially enhance the ... , while also reducing the side effect profile of these ...
Cached Medicine Technology:Mylan's Dey Pharma Partners with Meda to Market EpiPen® Auto-Injector in Europe 2Mylan's Dey Pharma Partners with Meda to Market EpiPen® Auto-Injector in Europe 3Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Maintains Target Price of $2.10 2
... The Equalizer With 384 Well Plate ... the revolutionary features of the original Equalizerexpandable and ... autoclavable components, and in-lab calibration capabilities. In addition, ... tips down to 4.5mm for loading and accessing ...
... Plate Capability The Equalizer 384 includes ... and equal tip spacing, choice of two software ... addition, this model allows you to evenly space ... accessing many gels and for use with 384 ...
... Tip System A lower cost alternative to ... perform multi-sample transfers between two different vessel configurations. ... tip spacing can be quickly and easily adjusted ... well plates. Ergonomic Design for Unparalleled Comfort ...
... Tip System A lower cost alternative to ... perform multi-sample transfers between two different vessel configurations. ... tip spacing can be quickly and easily adjusted ... well plates. Ergonomic Design for Unparalleled Comfort ...
Medicine Products: